NO20033782L - Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer - Google Patents
Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymerInfo
- Publication number
- NO20033782L NO20033782L NO20033782A NO20033782A NO20033782L NO 20033782 L NO20033782 L NO 20033782L NO 20033782 A NO20033782 A NO 20033782A NO 20033782 A NO20033782 A NO 20033782A NO 20033782 L NO20033782 L NO 20033782L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- methyl cellulose
- solid dispersion
- hydroxypropyl methyl
- cellulose phthalate
- Prior art date
Links
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 title 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 239000007962 solid dispersion Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0104752.1A GB0104752D0 (en) | 2001-02-27 | 2001-02-27 | Pharmaceutical compositions |
| PCT/SE2002/000327 WO2002067904A1 (en) | 2001-02-27 | 2002-02-25 | Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033782D0 NO20033782D0 (no) | 2003-08-26 |
| NO20033782L true NO20033782L (no) | 2003-08-26 |
Family
ID=9909545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033782A NO20033782L (no) | 2001-02-27 | 2003-08-26 | Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040138231A1 (enExample) |
| EP (1) | EP1365746A1 (enExample) |
| JP (1) | JP2004527489A (enExample) |
| KR (1) | KR20040011469A (enExample) |
| CN (1) | CN1533268A (enExample) |
| BR (1) | BR0206960A (enExample) |
| CA (1) | CA2435815A1 (enExample) |
| GB (1) | GB0104752D0 (enExample) |
| IL (1) | IL156830A0 (enExample) |
| MX (1) | MXPA03006746A (enExample) |
| NO (1) | NO20033782L (enExample) |
| NZ (1) | NZ527080A (enExample) |
| WO (1) | WO2002067904A1 (enExample) |
| ZA (1) | ZA200305386B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| WO2004105728A2 (en) * | 2003-05-27 | 2004-12-09 | Ranbaxy Laboratories Limited | Solid dispersions of cefpodoxime proxetil and processes for their preparation |
| KR100531612B1 (ko) * | 2003-08-12 | 2005-11-28 | 경동제약 주식회사 | 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제 |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20110034478A1 (en) * | 2008-04-15 | 2011-02-10 | Schering-Plough Corporation | Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs |
| DK2346495T4 (da) * | 2008-10-07 | 2023-08-28 | Kudos Pharm Ltd | Farmaceutisk formulering 514 |
| US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
| CN104188893A (zh) * | 2014-08-18 | 2014-12-10 | 赵明亮 | 一种盐酸环丙沙星口服固体制剂及其制备工艺 |
| PT3518924T (pt) | 2016-09-30 | 2022-10-27 | Salix Pharmaceuticals Inc | Formas de dispersão sólidas de rifaximina |
| WO2025078941A1 (en) * | 2023-10-09 | 2025-04-17 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of pirtobrutinib |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57120518A (en) * | 1981-01-19 | 1982-07-27 | Tanabe Seiyaku Co Ltd | Preparation of microcapsule |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| TW212139B (enExample) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| ATE159426T1 (de) * | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
| WO1995005809A1 (en) * | 1993-08-20 | 1995-03-02 | Nippon Shinyaku Co., Ltd. | Gastric remaining preparation, swollen molding, and production process |
| ES2232131T3 (es) * | 1998-05-02 | 2005-05-16 | Astrazeneca Ab | Derivados heterociclicos que inhiben el factor xa. |
| EP1239831B1 (en) * | 1999-12-23 | 2012-10-31 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
-
2001
- 2001-02-27 GB GBGB0104752.1A patent/GB0104752D0/en not_active Ceased
-
2002
- 2002-02-25 CN CNA028056256A patent/CN1533268A/zh active Pending
- 2002-02-25 NZ NZ527080A patent/NZ527080A/en unknown
- 2002-02-25 MX MXPA03006746A patent/MXPA03006746A/es unknown
- 2002-02-25 WO PCT/SE2002/000327 patent/WO2002067904A1/en not_active Ceased
- 2002-02-25 EP EP02700946A patent/EP1365746A1/en not_active Withdrawn
- 2002-02-25 BR BR0206960-1A patent/BR0206960A/pt not_active IP Right Cessation
- 2002-02-25 IL IL15683002A patent/IL156830A0/xx unknown
- 2002-02-25 JP JP2002567272A patent/JP2004527489A/ja active Pending
- 2002-02-25 CA CA002435815A patent/CA2435815A1/en not_active Abandoned
- 2002-02-25 KR KR10-2003-7011174A patent/KR20040011469A/ko not_active Withdrawn
- 2002-02-25 US US10/468,246 patent/US20040138231A1/en not_active Abandoned
-
2003
- 2003-07-11 ZA ZA200305386A patent/ZA200305386B/en unknown
- 2003-08-26 NO NO20033782A patent/NO20033782L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03006746A (es) | 2003-10-24 |
| ZA200305386B (en) | 2004-10-11 |
| JP2004527489A (ja) | 2004-09-09 |
| US20040138231A1 (en) | 2004-07-15 |
| NO20033782D0 (no) | 2003-08-26 |
| CN1533268A (zh) | 2004-09-29 |
| KR20040011469A (ko) | 2004-02-05 |
| IL156830A0 (en) | 2004-02-08 |
| EP1365746A1 (en) | 2003-12-03 |
| GB0104752D0 (en) | 2001-04-18 |
| BR0206960A (pt) | 2004-03-09 |
| CA2435815A1 (en) | 2002-09-06 |
| NZ527080A (en) | 2005-02-25 |
| WO2002067904A1 (en) | 2002-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043866L (no) | Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat | |
| NO20033782D0 (no) | Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer | |
| NO20042842L (no) | Farmasoytiske formuleringer av platina-derivat | |
| NO20014893D0 (no) | Farmasöytiske sammensetninger av erythropoietin | |
| DK1311285T3 (da) | Flydende farmaceutisk præparat, som omfatter et erythropoietinderivat | |
| NO20035729L (no) | Piperidinderivater som er nyttige som modulatorer av kemokin-reseptor-aktivitet | |
| NO20035157D0 (no) | Lungeadministrering av kjemisk modifisert insulin | |
| NO20032181D0 (no) | Anvendelse av CCI-779 som et antineoplastisk middel | |
| FIU20000164U0 (fi) | Uusi farmaseuttinen formulaatio | |
| NO20012248L (no) | Farmasöytisk preparat av moksifloksacin | |
| NO20015149L (no) | Nytt farmasöytisk preparat | |
| NO20040860L (no) | Farmasoytisk sammensetning som innbefatter lumiracoxib | |
| NO20013205L (no) | Farmasöytiske formuleringer i hydroksypropylmetylcellulosekapsler | |
| NO20015148D0 (no) | Nytt farmasöytisk preparat | |
| NO20015530L (no) | Fremgangsmåte til fremstilling av inherente mikrobedrepende polymeroverflater | |
| DK1475379T3 (da) | Anvendelse af scopinesterderivater til fremstilling af lægemidler | |
| AU2002346457A1 (en) | Pharmaceutical formulations comprising indolinone derivatives | |
| NO20021866D0 (no) | Ciclesonid-inneholdende vandig farmasöytisk blanding | |
| WO2006115712A3 (en) | Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability | |
| NO995945L (no) | Nye forbindelser | |
| NO20015104L (no) | Nytt farmasöytisk preparat | |
| NO20043007L (no) | Farmasoytisk suspensjon for oral administrering | |
| NO20015105D0 (no) | Nytt farmasöytisk preparat | |
| NO20015532L (no) | Fremgangsmåte til fremstilling av inherente mikrobedrepende polymeroverflater | |
| NO20042022L (no) | Fast legemiddelformulering som inneholder pipiperazinurea-derivat og fremgangsmate for fremstilling av formuleringen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |